Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 485

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 485
---
21, 2025).10.3Amended and Restated Registration Rights Agreement, dated as of September 22, 2025, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company and certain security holders (incorporated by reference to Exhibit 10.2 of our Current Report on Form 8-K (File No.001-41351),filed with the SEC on September 26, 2025).10.4*Form of Indemnification Agreement of Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.11 of Amendment No. 1 to Denali’s registration statement on Form S-4 filed with the SEC on April 21, 2025).10.5*2024 Semnur Pharmaceuticals, Inc. Stock Option Plan. (incorporated by reference to Exhibit 10.12 of Amendment No. 6 to Denali’s registration statement on Form S-4 filed with the SEC on August 11, 2025).10.6*Form of Stock Option Grant Notice and Form of Stock Option Agreement under 2024 Semnur Pharmaceuticals, Inc. Stock Option Plan (incorporated by reference to Exhibit 10.13 of Amendment No. 6 to Denali’s registration statement on Form S-4 filed with the SEC on August 11, 2025).10.7#Sponsor Interest Purchase Agreement, dated as of August 30, 2024, by and between Denali Capital Global Investments LLC and Scilex Holding Company (incorporated by reference to Exhibit 10.3 to Denali’s Current Report on Form 8-K (File No. 001-41351), filed with the SEC on September 5, 2024).10.8^Master Services Agreement—SP-102, dated as of January 27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC. (incorporated by reference to Exhibit 10.19 of Amendment No. 7 to Denali’s registration statement on Form S-4 filed with the SEC on August 12, 2025).10.9Amendment No. 1 to Master Services Agreement, dated as of April 26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC. (incorporated by reference to Exhibit 10.20 of Amendment No. 7